First approved gene therapy for a hereditary eye disease carried out in Germany

A large number of genes are associated with retinal diseases. RPE65-associated retinal dystrophies are a clinically heterogeneous group of hereditary retinal diseases that have in common a progressive decline in retinal function. Affected persons suffer from retinal degeneration which leads to a loss of visual field and visual acuity up to blindness.

The new therapy marks the beginning of a new era in ophthalmology. „Finally, a new treatment option can be offered to patients suffering from a previously untreatable retinal disease,“ said Professor Siegfried Priglinger, Director of the Eye Clinic.

contact for scientific information:
Professor Dr. Siegfried Priglinger
Director of the Department of Ophthalmology
University Hospital of LMU Munich
Mathildenstrasse 8, 80336 Munich, Germany

Please direct enquiries to

PD Dr. Claudia Priglinger

Maximilian Gerhardt

Prof. Dr. Günther Rudolph

Scroll to Top
Scroll to Top